XTalks

MARCH 8, 2022

On International Women’s Day, Xtalks is celebrating women’s leadership in the life sciences by highlighting some of the female leaders at the forefront of scientific discovery, as well as the continuing challenges of attaining more equitable representation. Challenges in Women’s Leadership.

Life Science 105

Life Science Gene Therapy DNA Vaccine 105

XTalks

SEPTEMBER 29, 2021

Life science workers are one of the most common areas of work that could not eliminate all visits to the office or lab during the COVID-19 pandemic. Additionally, these life science companies are now trying to find the new normal for many of their employees to accommodate the new lifestyle they have embraced.

Life Science 122

Life Science HR Scientist Genetic Disease 122

XTalks

OCTOBER 29, 2024

Genomic sequencing is a window into our genetic makeup. The GUARDIAN (Genomic Uniform-screening Against Rare Diseases In All Newborns) study, recently published in the Journal of the American Medical Association (JAMA) , highlights how adding genome sequencing to newborn screening could reshape early detection for rare genetic conditions.

Genome 95

Genome Genomics Genetics Life Science 95

pharmaphorum

NOVEMBER 7, 2022

This month, we highlight new appointments from Lumeris, Lineage Cell Therapeutics, 1910 Genetics, and ADC Therapeutics. . ” Patrick Genestin, 1910 Genetics . “I am excited to join 1910 Genetics at such a pivotal time for the company,” Genestin said. Ben Grabski, Lumeris.

Life Science 105

Life Science Genetics Business Development Marketing 105

XTalks

JUNE 12, 2024

It leverages various patient-specific factors, including genetics, age, weight, organ function and even lifestyle, to determine the most appropriate dosage for each individual. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 97

Life Science Pharmacy Doctor Doctors 97

XTalks

DECEMBER 22, 2021

If the past year is anything to go by, then 2022 will also be a year marked by continued innovations in the life sciences. Here is a look at some life science trends to expect in the coming year, including key themes and topics in the pharmaceutical, biotechnology and medical device industries to keep an eye out for in 2022.

Life Science 98

Life Science RNA Vaccination Vaccine 98

Pharmaceutical Technology

FEBRUARY 2, 2023

Last December, GSK and Wave Life Sciences entered a strategic partnership to drive the discovery and development of oligonucleotide therapies for new genetic targets. The post US FDA approves GSK’s Jesduvroq to treat anaemia of CKD appeared first on Pharmaceutical Technology.

FDA Approval 264

FDA Approval Life Science Genetics Trials 264

XTalks

MAY 23, 2024

One of the more intriguing developments in cancer research in recent years is the growing understanding of clonal hematopoiesis, a phenomenon where blood cells expand from a single clone due to genetic mutations. Clonal hematopoiesis increases in prevalence with age and can precede hematologic malignancies.

Genetics 114

Genetics Research Genome Genomics 114

XTalks

NOVEMBER 26, 2024

BridgeBio has been highly active in the genetic diseases space. Its investigational therapy infigratinib recently received Breakthrough Therapy designation, becoming the first-ever potential treatment for achondroplasia — a genetic condition affecting bone growth — to achieve this milestone.

Genetic Disease 105

Genetic Disease Genetics Protein Clinical Development 105

XTalks

SEPTEMBER 14, 2022

In this episode, Ayesha discussed the FDA approval of Sanofi’s enzyme replacement therapy Xenpozyme for the treatment of non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD), a rare genetic lysosomal storage disease, in adults and pediatric patients.

Life Science 90

Life Science FDA Approval Insulin Drugs 90

Pharmaceutical Technology

MAY 24, 2023

The AMP programme is a public-private partnership between a number of biopharmaceutical and life sciences companies, the US Food and Drug Administration (FDA) and the National Institutes of Health (NIH), along with non-profit and other organisations.

Gene Therapy 242

Gene Therapy Gene Development Manufacturing 242

XTalks

JANUARY 6, 2025

CF is a progressive genetic disease caused by defective CFTR proteins, which are crucial for regulating salt and water movement in cells. Vertex remains committed to advancing CF research, with plans to expand the impact of their CFTR modulators and explore new genetic mutations.

Gene Therapy 105

Gene Therapy Protein Genetic Disease Gene 105

XTalks

SEPTEMBER 30, 2020

The two studies were recently published online in the journal Science, both of which were led by Jean-Laurent Casanova, an infectious disease geneticist at Rockefeller University. Casanova’s lab is now searching for the genetic driver behind the autoantibodies. Autoimmune Attack and COVID-19 Symptom Severity.

Antibody 135

Antibody Genetics Research In-Vitro 135

XTalks

APRIL 13, 2022

Gentamicin is the preferred treatment for newborns with infections like sepsis but about one in 500 babies have a genetic variant that makes them susceptible to gentamicin-induced hearing loss. Genedrive’s Genetic Test Can Prevent Hearing Loss in Babies Through Personalized Treatment.

Life Science 52

Life Science Genetics Research Development 52

XTalks

JANUARY 5, 2022

Ayesha also discussed some of the predicted trends in the life sciences for 2022. These include the continued promise of RNA-based vaccines as well as therapeutics based on RNA editing approaches for the treatment of various conditions including rare genetic diseases. Key Trends in the Life Sciences to Look Forward to in 2022.

Life Science 52

Life Science RNA Vaccine Vaccination 52

BioPharma Reporter

DECEMBER 16, 2022

GSK and genetic medicines company, Wave Life Sciences, have announced a strategic collaboration to advance oligonucleotide therapeutics across multiple disease areas.

Life Science 52

Life Science Genetics Development Medicine 52

XTalks

FEBRUARY 4, 2025

Current Share Price: The announcement follows a $115 million Series D financing in December 2024, co-led by Frazier Life Sciences and Deep Track Capital, with participation from Janus Henderson Investors and Logos Capital. MZE829 aims to mimic a protective genetic variant of APOL1.

Clinical Trials 66

Clinical Trials Clinical Trials Trials Genetics 66

XTalks

MARCH 19, 2025

Elevidys is the first FDA-approved gene therapy for DMD a rare genetic disorder characterized by progressive muscle degeneration. Elevidys aims to address the underlying genetic cause by introducing a functional version of the dystrophin gene, which is essential for muscle function. Sarepta is reviewing all available data.

Gene Therapy 80

Gene Therapy Gene Genetics Clinical Trials 80

Scienmag

JULY 4, 2022

Medical and life science researchers will benefit from the most comprehensive atlas yet of genetic data on zebrafish, newly published research suggests. The atlas will help researchers to better study conditions from various types of cancer (e.g. skin cancer), heart disease, and neurodegeneration.

Genetics 61

Genetics Research Life Science 61

World of DTC Marketing

JANUARY 24, 2022

A group of early-stage life science investors and biotech CEOs joined together with a prominent patient advocate to speak out against H.R.3, The panel was hosted by the life sciences venture capital coalition Incubate and held at the National Press Club. Only about $2.2 3, known as the Lower Drug Costs Now Act.

Life Science 225

Life Science Drugs Development Genetic Disease 225

Pharmaceutical Technology

FEBRUARY 13, 2023

Gene therapies are an attractive way of targeting the underlying genetic mutations, but traditional approaches cannot be used while targeting mutations for Dravet Syndrome, forcing researchers to develop new ways. SK Life Science is a subsidiary of SK, a South Korean holding company.

Research 264

Research Gene Gene Therapy Genome 264

XTalks

MARCH 28, 2024

Duvyzat, a histone deacetylase (HDAC) inhibitor that works to reduce inflammation and muscle loss, is the first nonsteroidal drug approved to treat patients with all genetic variants of DMD. According to the FDA, life expectancy for those with DMD has increased over the years, with some patients surviving beyond 30 years.

FDA Approval 105

FDA Approval Genetics Gene Therapy Gene 105

BioSpace

JUNE 13, 2024

Morgan’s life sciences venture capital arm on Thursday announced it closed its first biotech fund, targeting companies in cardiometabolic disease, immunology, oncology and genetic medicine.

Life Science 83

Life Science Genetics Medicine 83

Pharmaceutical Technology

MAY 4, 2023

Forge Biologics and global life sciences company Labcorp have announced a strategic adeno-associated virus (AAV) gene therapy development and manufacturing collaboration.

Gene Therapy 256

Gene Therapy Gene Development Manufacturing 256

XTalks

AUGUST 7, 2024

Lawreen is a seasoned biotech and life science professional with over 25 years of experience. Tune into the episode to hear Lawreen’s perspectives as both a life sciences professional and rare disease patient advocate. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 52

Life Science Scientist Production Research 52

XTalks

SEPTEMBER 27, 2023

With their extensive genetic engineering capabilities, they are paving the way for potentially better and safer treatments for conditions including blood cancers such as multiple myeloma, solid tumors like breast and ovarian cancer, and rare genetic liver diseases. Scientists working at Poseida Therapeutics.

Life Science 59

Life Science Genetic Engineering Engineer Gene Therapy 59

Pharmaceutical Technology

JUNE 4, 2023

Encoded Therapeutics develops gene therapies for the treatment of severe genetic disorders. The company’s drug ETX-101, comprising a recombinant adeno-associated virus (AAV9) vector, is under development for the treatment of Dravet syndrome. The company is headquartered in South San Francisco, California, US.

Gene 262

Gene Gene Therapy Genetics DNA 262

STAT News

SEPTEMBER 12, 2022

In the life sciences industry, where company names derived from “biology” or “genetics” are a dime a dozen, it helps to have a brand that stands out. Pretzel Therapeutics is one of this year’s more creative gambits, launching Monday with $72.5 Continue to STAT+ to read the full story…

Genetic Disease 98

Genetic Disease Life Science Genetics Branding 98

XTalks

DECEMBER 9, 2024

This initiative is particularly impactful for rare diseases and genetic disorders, where traditional endpoints may be infeasible. Programs like the Rare Disease Endpoint Advancement Pilot encourage collaboration with the FDA to establish novel surrogate endpoints.

Clinical Trials 105

Clinical Trials Clinical Trials Compliance Trials 105

pharmaphorum

OCTOBER 2, 2020

Swiss medical data specialist Sophia Genetics has raised $110 million in an oversubscribed funding round that will be used to boost its headcount and international presence and prepare to take its shares public. The post $110m financing sets up US, Asia expansion for Sophia Genetics appeared first on.

Genetics 59

Genetics Genome Genomics Life Science 59

XTalks

DECEMBER 4, 2024

CAMP4’s RNA-based therapies focus on genetic diseases like urea cycle disorders, while Rapport’s small molecules aim to address epilepsy, pain and bipolar disorder. Jupiter joins a wave of biotech IPOs this year, stepping into a competitive space while broadening treatment options for CNS patients.

Bioavailability 111

Bioavailability Genetic Disease Marketing RNA 111

XTalks

MARCH 2, 2022

The editorial team discussed the encouraging growth seen in recent years in rare disease clinical research in the life science industries, providing hope for improved diagnosis, care and treatments for patients with rare diseases. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 52

Life Science Clinical Trials Clinical Trials Trials 52

Intouch Solutions

MARCH 18, 2025

The POV highlights the multifaceted nature of health determinants, noting that while genetics play a role, many other factors such as social, economic, and environmental elements are equally important. These determinants are crucial for engaging with digital health tools and services, which can significantly impact health outcomes.

Life Science 59

Life Science Genetics Development Marketing 59

XTalks

FEBRUARY 28, 2024

Advancements in rare disease research are leading to innovative new treatments for various rare conditions, including genetic disorders, which make up just over 70 percent of all rare diseases. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 52

Life Science Research Genetics Drugs 52

Pharmaceutical Technology

MAY 22, 2023

This new facility complements the bioprocess design centre and customer experience centre, the two operational lab facilities of Thermo Fisher with the latest life science, analytical, and bioprocessing technologies. The bioprocess design centre offers expertise in bioprocessing and process scale-up.

Genetic Analysis 147

Genetic Analysis Manufacturing Drugs Vaccination 147

XTalks

JUNE 23, 2022

Amvuttra RNAi Therapeutic Wins FDA Approval for Rare Genetic Protein Disorder. Subscribe to the Xtalks Life Science Podcast to never miss a new episode. Read the full articles here: Eli Lilly’s Olumiant Wins FDA Approval as First Systemic Treatment for Alopecia Areata.

Life Science 52

Life Science FDA Approval Protein Drugs 52

XTalks

SEPTEMBER 22, 2022

can act on existing genetic mutations to trigger inflammation and the development of cancer. Subscribe to the Xtalks Life Science Podcast to never miss a new episode. The research findings revealed that people who live in polluted areas have a higher risk of lung cancer, and that particulate matter smaller than 2.5

Life Science 52

Life Science Scientist Development Genetics 52